Kai Chen

Kai Chen


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2022 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
ZCZihan Cui
Zihan Cui
DLDapeng Li
Dapeng Li
JZJun Zhao
Jun Zhao
KCKai Chen
Kai Chen

6 November 2023 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
LLLinlin Lu
Linlin Lu
ZNZihe Niu
Zihe Niu
ZCZhujun Chao
Zhujun Chao
CFCuiping Fu
Cuiping Fu
KCKai Chen
Kai Chen
YSYaqin Shi
Yaqin Shi

1 April 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
XWXinan Wan
Xinan Wan
MFMingxing Fang
Mingxing Fang
TCTingting Chen
Tingting Chen
HWHuihui Wang
Huihui Wang
QZQin Zhou
Qin Zhou
KCKai Chen
Kai Chen

1 April 2021 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
GGGuanghui Gao
Guanghui Gao
XZXiao-Dong Zhang
Xiao-Dong Zhang
HQHu Qu
Hu Qu
BYBing Yao
Bing Yao
YZYuxi Zhou
Yuxi Zhou
JXJunying Xu
Junying Xu
Background: Immune checkpoint inhibitors blocking programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have emerged as effective treatment options for cancer. However, immunotherapy is only effective in a subset of patients. Identifying effective biomarkers to predict the treatment response to PD-1/PD-L1 inhibitors remains an unmet clinical need. Methods: This study retrospectively analyzed clinical information and genetic profiling results of 16,013 samples from Chinese patients with various cancer types in order to investigate the prevalence of CD274 (also known as PD-L1) amplification in various cancer types and its association with existing PD-1/PD-L1 biomarkers, including tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1 expression. Results: Amplification of CD274 was identified in 174 samples with an overall prevalence of 1.09% among all cancer types in the cohort. The prevalence of CD274 amplification in different cancer types and histological subtypes of lung cancer was varied, with cervical cancer having the highest prevalence. Distinct distributions of TMB, MSI, and PD-L1 expression between CD274-amplified and wild-type samples were observed in several cancer types as well as among different histological subtypes of lung cancer. Conclusions: Although CD274 amplification was only observed in a small proportion of patients, it demonstrated an association with TMB, MSI, and PD-L1 expression in several common cancer types. The molecular features of CD274 in different cancer types are heterogeneous. The role of CD274 amplification as a novel biomarker of PD-1/PD-L1 inhibitors remains to be characterized in future prospective clinical studies.

13 October 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
YWYan Wu
Yan Wu
DLDapeng Li
Dapeng Li
MWMengyao Wu
Mengyao Wu
YYYing Yang
Ying Yang
MSMeng Shen
Meng Shen
KCKai Chen
Kai Chen
Background: Immune-related adverse events (irAEs) have drawn a lot of attention lately as a result of the predominance of immunotherapy in advanced non-small cell lung cancer (NSCLC). However, the clinical evidence for irAEs in real life is limited. In this paper, the occurrence of irAEs in Chinese NSCLC patients was examined, and possible risk factors for the emergence of severe irAEs were discovered.Methods: Our retrospective investigation assessed the occurrence of adverse events (AEs) and prognosis of 213 patients who received immunotherapy for NSCLC. Using univariate and multivariate logistic regression models, the association between clinicopathological traits and the incidence of severe irAEs was investigated. To assess the prognostic impact of irAEs, survival data was analyzed.Results: Among the 213 NSCLC patients, 122 (57.3%) had irAEs of any grade, and 38 (17.8%) had high-grade (grade 3-5) AEs. Baseline peripheral absolute eosinophil count (AEC) (HR 6.58, 95% CI: 1.5-28.8, P=0.012) was found to be an independent predictor of high-grade irAEs by multivariate analysis. The survival analysis revealed that patients with severe irAEs had worse OS (15.7 vs. 20.8 months, 95% CI: 11.6-19.8 vs. 16.0-25.5, P=0.026).Conclusion: According to our findings, the peripheral absolute eosinophil count (AEC) is a reliable indicator of severe irAEs in NSCLC. Serious irAEs that occur in patients often reflect poor prognoses. In the future, high-grade irAEs should receive more attention.

1 May 2022 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
YSYaqin Shi
Yaqin Shi
MSMeng Shen
Meng Shen
MXMengdan Xu
Mengdan Xu
MTMin Tao
Min Tao
KCKai Chen
Kai Chen
QZQingqing Zhu
Qingqing Zhu
Purpose: The RAD51 family of genes, including RAD51 and the five RAD51-like paralogs (RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3), are known to be crucially associated with DNA damage repair pathway. Increasing evidence indicated that RAD51 family members were implicated in breast cancer tumorigenesis. However, their biological roles and prognostic values in breast cancer have yet to be clarified. Methods: In this study, by using the Oncomine and GEPIA databases, we explored the transcriptional levels of RAD51 family members in breast cancer. Besides, the associations between RAD51 family expression and clinical features were evaluated by using the UALCAN database and Kaplan–Meier (KM) Plotter. We also analyzed the mutations of the RAD51 family and differentially altered genes from the cBioPortal database. Results: We found that RAD51 mRNA was significantly elevated in breast cancer samples than in normal tissues, while XRCC2 mRNA was downregulated. Besides, a remarkable correlation was detected between the expression of RAD51/RAD51B/XRCC2 genes and the breast cancer stage. Survival analysis utilizing the KM Plotter indicated that high RAD51 and XRCC3 mRNA was associated with a poor prognosis. Conversely, RFS data suggested that high levels of RAD51B/RAD51C/RAD51D/XRCC2 were associated with a favorable prognosis. Moreover, a high genetic variation rate of RAD51C (7%) was detected in breast cancer patients. Conclusion: Conclusively, we implied that RAD51 and XRCC3 might be potential targets for precision therapy in breast cancer and the RAD51B/RAD51C/RAD51D/XRCC2 genes have significant values for breast cancer prognosis.